Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MONDELEZ INTERNATIONAL INC Common Stock vs Neurocrine Biosciences Inc — how do they compare? MONDELEZ INTERNATIONAL INC Common Stock trades at $60.33 (market cap $77.43B), while Neurocrine Biosciences Inc trades at $141.13 (market cap $14.36B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 5.4× Neurocrine Biosciences Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.43% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold MONDELEZ INTERNATIONAL INC Common Stock for 107 Days and Neurocrine Biosciences Inc for 23 Days on average.
| MDLZ | NBIX | |
|---|---|---|
Market Cap | $77.43B | $14.36B |
Volume | 7,695,104 | 1,237,180 |
Sector | Consumer Staples | Health |
52-Week High | $64.99 | $185.50 |
52-Week Low | $51.51 | $123.10 |
Typical Hold Time | 107 Days | 23 Days |
Enterprise Value | $97.78B | $14.37B |
Dividend Yield | 3.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mondelez International (MDLZ) trades at $59.38, down 0.4% with a bearish technical signal despite beating earnings expectations for three consecutive quarters. The company maintains solid fundamentals with $38.54B revenue, 8.86% net margin, and strong analyst support (76% buy ratings). Recent developments include a dividend increase to $0.52 per share and new product launches like Toblerone Diamond Truffles.
MDLZ presents a compelling long-term opportunity with attractive valuation metrics (P/E 22.22) and 14% upside to consensus price target of $70.29. Key risks include cocoa cost pressures and competitive snack market dynamics, but the company's global brand strength and consistent execution support bullish outlook for patient investors.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
